Mattias Häggblom's questions to AstraZeneca PLC (AZN) leadership • Q1 2025
Question
Mattias Häggblom asked about the likelihood of the pharmaceutical industry uniting its messaging on pricing and tariffs, and inquired where AstraZeneca's internal models might deviate from consensus regarding its $80 billion revenue target for 2030.
Answer
CEO Pascal Soriot expressed his belief that the industry is coming together to address tariffs and the innovation funding imbalance between the U.S. and Europe. CFO Aradhana Sarin suggested that areas of potential upside versus consensus for the 2030 target include the biopharma and rare disease portfolios (e.g., respiratory, CVRM, oral PCSK9) and the company's proprietary ADC and cell therapy pipelines, which may not be fully valued by the market.